Researchers have successfully demonstrated how an electronic device implanted directly into the brain can detect, stop and even prevent epileptic seizures.
These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications.
The researchers, from the University of Cambridge, the École Nationale Supérieure des Mines and INSERM in France, implanted the device into the brains of mice, and when the first signals of a seizure were detected, delivered a native brain chemical which stopped the seizure from progressing. The results, reported in the journal Science Advances, could also be applied to other conditions including brain tumours and Parkinson’s disease.
The work represents another advance in the development of soft, flexible electronics that interface well with human tissue. “These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications,” said Professor George Malliaras, the Prince Philip Professor of Technology in Cambridge’s Department of Engineering, who led the research.
While there are many different types of seizures, in most patients with epilepsy, neurons in the brain start firing and signal to neighbouring neurons to fire as well, in a snowball effect that can affect consciousness or motor control. Epilepsy is most commonly treated with anti-epileptic drugs, but these drugs often have serious side effects and they do not prevent seizures in three out of 10 patients.
In the current work, the researchers used a neurotransmitter which acts as the ‘brake’ at the source of the seizure, essentially signalling to the neurons to stop firing and end the seizure. The drug is delivered to the affected region of the brain by a neural probe incorporating a tiny ion pump and electrodes to monitor neural activity.
When the neural signal of a seizure is detected by the electrodes, the ion pump is activated, creating an electric field that moves the drug across an ion exchange membrane and out of the device, a process known as electrophoresis. The amount of drug can be controlled by tuning the strength of the electric field.
“In addition to being able to control exactly when and how much drug is delivered, what is special about this approach is that the drugs come out of the device without any solvent,” said lead author Dr Christopher Proctor, a postdoctoral researcher in the Department of Engineering. “This prevents damage to the surrounding tissue and allows the drugs to interact with the cells immediately outside the device.”
The researchers found that seizures could be prevented with relatively small doses of drug representing less than 1% of the total amount of drug loaded into the device. This means the device should be able to operate for extended periods without needing to be refilled. They also found evidence that the delivered drug, which was in fact a neurotransmitter that is native to the body, was taken up by natural processes in the brain within minutes which, the researchers say, should help reduce side effects from the treatment.
Although early results are promising, the potential treatment would not be available for humans for several years. The researchers next plan to study the longer-term effects of the device in mice.
Malliaras is establishing a new facility at Cambridge which will be able to prototype these specialised devices, which could be used for a range of conditions. Although the device was tested in an animal model of epilepsy, the same technology could potentially be used for other neurological conditions, including the treatment of brain tumours and Parkinson’s disease.
The Latest on: Epilepsy
via Google News
The Latest on: Epilepsy
- EEG Data May Help Aid Diagnosis, Treatment of Focal Epilepsyon February 24, 2021 at 4:07 am
An analysis of continuous EEG data suggests seizure onset in focal epilepsy follows circadian, multiday, and annual cycles in findings that could help diagnosis and treatment delivery.
- Sun Pharma to launch Brivaracetam for epilepsy treatment in Indiaon February 23, 2021 at 10:33 pm
Mumbai: Drug major, Sun Pharmaceutical Industries Limited, has recently announced that the company will introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy ...
- Pharmac knew of epilepsy drug change risks - inqueston February 23, 2021 at 10:26 pm
An inquest into the deaths of six people with epilepsy has revealed the drug buying agency knew a brand switch came with risks.
- Pharmac knew of epilepsy drug change risks within some patients, but went ahead with switchon February 23, 2021 at 8:39 pm
Pharmac knew there were clinical reasons some epilepsy patients would not tolerate a change to their medicines. But the drug buying agency went ahead with a switch that forced more than 10,000 people ...
- Global Epilepsy Drug Market Share, Growth, Trends, and Forecast 2021-2026on February 23, 2021 at 6:47 am
Selbyville Delaware, Market Study Report, LLC, has recently added a concise research on the Epilepsy Drug market ...
- Epilepsy Monitoring Device Market Outlook and Forecasts By Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysison February 23, 2021 at 6:09 am
Epilepsy Monitoring Device Market Size, Demand-sales, Suppliers By Key Applications Detailed Analysis and Growth Aspects on Manufacturing Landscapes and Regional Analysis "The report on the global ...
- Sun Pharma launches Belgian firm UCB epilepsy drug after patent expiryon February 23, 2021 at 3:56 am
Sun Pharmaceutical Industries has launched anti-epileptic drug Brivaracetam in multiple dosage forms, at an “affordable” price, the company said, without giving details.It’s brand Brevipil tablet was ...
- Sun Pharma to launch complete range of generic anti-epilepsy drugon February 23, 2021 at 3:00 am
Sun Pharma introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on Feb 21, while Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the mark ...
- Sun Pharma to launch range of Brivaracetam drug for epilepsy treatmenton February 23, 2021 at 2:05 am
Sun Pharma's new drug is approved DGCI as an adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.Long-term studies indicate that the ...
- Epilepsy drug deaths: Medsafe told Pharmac it was 'not desirable' to switch brandson February 22, 2021 at 8:08 pm
Pharmac was told of concerns around changes to funding for an epilepsy drug now at the centre of an inquest into six deaths.
via Bing News